Cascade of care for children and adolescents with chronic hepatitis C

Chronic hepatitis C virus(HCV)infection presents a significant global public health burden.In 2015,over 400000 deaths worldwide were attributed to HCV infection.This led the World Health Organization(WHO)in 2016 to set the ambitious goal of eliminating HCV by 2030.Adult-centered guidelines have been established in order to provide direction for healthcare professionals,allowing integration of the newest screening policies and therapeutic strategies into their practices.However,for children and adolescents,HCV is a significant,unrecognized public health problem.HCV infection rates in the United States in women of childbearing age and those who are pregnant have increased in parallel with the rising opioid epidemic.An estimated 29000 women with HCV infection gave birth each year from 2011 to 2014 in the United States,with approximately 1700 of their infants being infected with HCV.Newer HCV-specific therapeutics,namely direct acting antivirals(DAA),has brought a new and highly successful approach to treatment of hepatitis C.Recent studies have confirmed similar levels of effectiveness and safety of DAA therapies in the pediatric population.Thus,an enhanced cascade of care,which should include the population under 18 years of age,can help achieve the WHO goal by focusing on elimination in the youngest populations.This review will present an overview of the natural history,clinical features,and management of HCV in children and adolescents.